clinical trial · NCT07331987
Efficacy and Safety of Probiotics for Anxiety Depression
Moon (Guangzhou) Biotechnology Co., Ltd.·N/A·not yet recruiting·n = 60
Anxiety DepressionProbioticPlaceboEscitalopram
brief summary
This randomized, double-blind, placebo-controlled study will enroll 60 individuals with mild-to-moderate anxiety depression. Following a 3-month intervention and a 1-month follow-up period, the study aims to: 1) evaluate the efficacy of probiotics by comparing anxiety, depression, and sleep scores to baseline; and 2) investigate the safety and underlying mechanisms by analyzing changes in serum biomarkers, gut microbiota, and related metabolites.
started
Mar 1, 2026
primary completion
Dec 30, 2026
completion
Feb 28, 2027
last updated
Jan 15, 2026
official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Efficacy and Safety of Probiotics in Participants With Anxiety Depression
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol